Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions.

Authors:
Margolskee A; Darwich AS; Galetin A; Rostami-Hodjegan A; Aarons L.

Journal:
AAPS J

Publication Year: 2015

DOI:
10.1208/s12248-015-9849-y

PMCID:
PMC4779109

PMID:
26667356

View on PubMed View on PMC View Publisher
Journal Information

Full Title: AAPS J

Abbreviation: AAPS J

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Drug Therapy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy.
Gorovits B; Azadeh M; Buchlis G and 12 more (2023) - Transparency Score: 3/6
Gastrointestinal Delivery of an mRNA Vaccine Using Immunostimulatory Polymeric Nanoparticles.
Kim H; Kirtane AR; Kim NY and 6 more (2023) - Transparency Score: 3/6
Lessons from CDER's Quality Management Maturity Pilot Programs.
Maguire J; Fisher A; Harouaka D and 9 more (2023) - Transparency Score: 2/6
Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepat…
Purohit V; Huh Y; Wojciechowski J and 5 more (2023) - Transparency Score: 4/6
Benchmarking the Quality Practices of Global Pharmaceutical Manufacturing to Advance Supply Chain R…
Fellows M; Friedli T; Li Y and 8 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:

"This work was performed under the OrBiTo Project, which has received support from the Innovative Medicines Joint Undertaking (http://www.imi.europa.eu) under Grant Agreement No. 115369."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025